Related Experiment Video
Updated: Jun 5, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Radiosensitivity of hepatocellular carcinoma]
C Hennequin1, L Quero, S Rivera
1Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1 avenue Claude-Vellefeaux, Paris, France. christophe.hennequin@sls.aphp.fr
Summary
Hepatocellular carcinoma (HCC) is increasingly common. Modern studies show HCC has similar radiosensitivity to other epithelial tumors, suggesting radiotherapy
Area of Science:
- Oncology
- Radiation Oncology
- Hepatobiliary Medicine
Context:
- Increasing incidence of hepatocellular carcinoma (HCC) in Western countries.
- Evolving role and discussion of radiotherapy in HCC management.
- Classical view of HCC as radioresistant is being re-evaluated.
Purpose:
- To investigate the radiosensitivity of hepatocellular carcinoma (HCC) cells.
- To review current understanding of HCC radiobiology and hepatic parenchyma radiosensitivity.
- To explore future therapeutic strategies combining radiotherapy with targeted therapies.
Summary:
- Radiobiologic studies on HCC cell lines indicate radiosensitivity comparable to other epithelial tumors.
- Clinical studies estimate the alpha/beta (α/β) ratio of HCC to be approximately 15 Gy.
- Normal hepatic parenchyma radiosensitivity is well-characterized, with available Normal Tissue Complication Probability (NTCP) models for guiding irradiation.
Impact:
- Challenges the traditional view of HCC as a radioresistant tumor.
- Provides data for optimizing radiotherapy planning in HCC patients.
- Highlights the potential of combining radiotherapy with targeted therapies for improved HCC treatment outcomes.
